Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer.

Sofie H Tolmeijer Emmy Boerrigter Takayuki Sumiyoshi Edmond M Kwan Sarah W S Ng Matti Annala Grainne Donnellan Cameron Herberts Guillemette E Benoist Paul Hamberg Diederik M Somford Inge M van Oort Jack A Schalken Niven Mehra Nielka P van Erp Alexander W Wyatt

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Early changes in ctDNA% are strongly linked to duration of first-line ARPI treatment benefit and survival in mCRPC and may inform early therapy switches or treatment intensification.

Keyphrases

circulating tumor
prostate cancer
small cell lung cancer
cell free
mesenchymal stem cells
combination therapy